Last mentioned: Mar 20, 2026
Public Criticism
Major editorials highlight the FDA's 'erratic' behavior as a threat to the broader innovation ecosystem.
Refusal to File
Senior regulator Vinay Prasad refuses to review Moderna's flu vaccine application, citing trial design concerns.
Grants Rescinded
The administration pulls back hundreds of millions in funding for mRNA-based research projects.
Trial Design Support
FDA officials reportedly signal support for Moderna's flu vaccine trial workaround and data submission plan.
Peak Valuation
Moderna reaches a market capitalization of $200 billion during the height of pandemic vaccine distribution.
House Republicans have introduced the Clean Water For All Life Act, a novel regulatory attempt to classify abortion pill remains as environmental pollutants. The bill seeks to mandate 'catch kits' for patients, ban mail-order medication, and impose severe criminal penalties on providers and users.
The FDA's recent refusal to review Moderna's flu vaccine application marks a significant pivot in the regulatory environment for mRNA technology. This shift, characterized by increasing political pressure and unpredictable oversight, threatens to stifle the very innovation that defined the pandemic response.
This page surfaces every story mentioning Food and Drug Administration across our healthcare coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running healthcare beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where Food and Drug Administration was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |